Rinvoq For Rheumatoid Arthritis
Since December 2019, Upadacitinib has been approved in few countries such as Germany. Upadacitinib (Rinvoq is the trade name) has proved its efficacy in treating the severe active form of rheumatoid arthritis.
Then, its use has become recommended in other countries such as U.S.A and England.
The National Institute of Health (NIH) has lately recommended Rinvoq for moderate to severe RA patients who showed no response to methotrexate and other treatment lines.
In this article, we are going to know more about Rinvoq, so let’s start.
Rinvoq is a Janus Kinase enzyme inhibitor (JAK inhibitor). Its main action is to block the cytokine’s pathway that activates the lymphocytes. So it’s considered an immune modifier drug, which can affect the immune system.
Sadly, the answer is yes. That is why you have to be careful while taking Rinvoq. It is better to discuss your condition first with your doctor before taking Rinvoq.
Studies have shown that patients treated with Rinvoq can catch different forms of infections very easily.
Before taking Rinvoq you must tell your doctor if you have any of the following medical conditions:
The recommended dose of Rinvoq is 15 mg per day. It is better to take your pill at the same time every day, with a full cup of water. Don’t crush the tablets or dissolve it.
Rinviqis a prescription only medicine
Image Source: https://www.rinvoq.com/